COVID-19 and the HIV continuum in people living with HIV enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts.
Antidepressant therapy
Care cascade
Depression
Depressive symptoms
Viral non-suppression
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
received:
16
08
2021
revised:
20
12
2021
accepted:
10
01
2022
pubmed:
26
3
2022
medline:
15
12
2022
entrez:
25
3
2022
Statut:
ppublish
Résumé
The COVID-19 pandemic disrupted the normal delivery of HIV care, altered social support networks, and caused economic insecurity. People with HIV (PWH) are vulnerable to such disruptions, particularly if they have a history of substance use. We describe engagement in care and adherence to antiretroviral therapy (ART) for PWH during the pandemic. From May 2020 to February 2021, 773 PWH enrolled in 6 existing cohorts completed 1495 surveys about substance use and engagement in HIV care during the COVID-19 pandemic. We described the prevalence and correlates of having missed a visit with an HIV provider in the past month and having missed a dose of ART in the past week. Thirteen percent of people missed an HIV visit in the past month. Missing a visit was associated with unstable housing, food insecurity, anxiety, low resiliency, disruptions to mental health care, and substance use including cigarette smoking, hazardous alcohol use, cocaine, and cannabis use. Nineteen percent of people reported missing at least one dose of ART in the week prior to their survey. Missing a dose of ART was associated with being a man, low resiliency, disruptions to mental health care, cigarette smoking, hazardous alcohol use, cocaine, and cannabis use, and experiencing disruptions to substance use treatment. Social determinants of health, substance use, and disruptions to mental health and substance use treatment were associated with poorer engagement in HIV care. Close attention to continuity of care during times of social disruption is especially critical for PWH.
Sections du résumé
BACKGROUND
The COVID-19 pandemic disrupted the normal delivery of HIV care, altered social support networks, and caused economic insecurity. People with HIV (PWH) are vulnerable to such disruptions, particularly if they have a history of substance use. We describe engagement in care and adherence to antiretroviral therapy (ART) for PWH during the pandemic.
METHODS
From May 2020 to February 2021, 773 PWH enrolled in 6 existing cohorts completed 1495 surveys about substance use and engagement in HIV care during the COVID-19 pandemic. We described the prevalence and correlates of having missed a visit with an HIV provider in the past month and having missed a dose of ART in the past week.
RESULTS
Thirteen percent of people missed an HIV visit in the past month. Missing a visit was associated with unstable housing, food insecurity, anxiety, low resiliency, disruptions to mental health care, and substance use including cigarette smoking, hazardous alcohol use, cocaine, and cannabis use. Nineteen percent of people reported missing at least one dose of ART in the week prior to their survey. Missing a dose of ART was associated with being a man, low resiliency, disruptions to mental health care, cigarette smoking, hazardous alcohol use, cocaine, and cannabis use, and experiencing disruptions to substance use treatment.
CONCLUSIONS
Social determinants of health, substance use, and disruptions to mental health and substance use treatment were associated with poorer engagement in HIV care. Close attention to continuity of care during times of social disruption is especially critical for PWH.
Identifiants
pubmed: 35331581
pii: S0376-8716(22)00092-8
doi: 10.1016/j.drugalcdep.2022.109355
pmc: PMC8837482
mid: NIHMS1791958
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
109355Subventions
Organisme : NIAID NIH HHS
ID : R01 AI170240
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA036926
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA036935
Pays : United States
Organisme : NIMH NIH HHS
ID : K08 MH118094
Pays : United States
Organisme : NIAAA NIH HHS
ID : K01 AA028193
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA036939
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interests No conflict declared.
Références
J Acquir Immune Defic Syndr. 2021 Nov 1;88(3):299-304
pubmed: 34651605
AIDS Res Ther. 2021 Jun 4;18(1):31
pubmed: 34088307
Health Aff (Millwood). 2009 Nov-Dec;28(6):1677-87
pubmed: 19887408
AIDS Behav. 2015 Nov;19(11):2087-96
pubmed: 25631320
Am J Public Health. 2016 Jan;106(1):e1-e23
pubmed: 26562123
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
AIDS Behav. 2021 May;25(5):1366-1372
pubmed: 33738698
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
AIDS Behav. 2021 Jan;25(1):49-57
pubmed: 32856176
AIDS Behav. 2007 Nov;11(6 Suppl):101-15
pubmed: 17768674
J Acquir Immune Defic Syndr. 2021 May 1;87(1):644-651
pubmed: 33443963
JAMA. 2019 Mar 5;321(9):844-845
pubmed: 30730529
AIDS Patient Care STDS. 2020 Apr;34(4):166-172
pubmed: 32324481
J Gen Intern Med. 2004 Nov;19(11):1111-7
pubmed: 15566440
J Urban Health. 2011 Jun;88(3):545-55
pubmed: 21409604
J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):100-8
pubmed: 19295340
Int J Epidemiol. 2021 Mar 3;50(1):31-40
pubmed: 33682886
J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):309-317
pubmed: 27787347
BMC Infect Dis. 2015 Jun 28;15:246
pubmed: 26123158
AIDS Behav. 2018 Mar;22(3):742-751
pubmed: 28612213
Clin Infect Dis. 2014 Nov 15;59(10):1471-9
pubmed: 25091306
Health Promot Pract. 2021 May;22(3):298-299
pubmed: 33709807
J Acquir Immune Defic Syndr. 2020 Sep 1;85(1):66-72
pubmed: 32530862
AIDS Behav. 2021 Dec;25(12):3909-3921
pubmed: 34173137
Am J Drug Alcohol Abuse. 2018;44(6):578-586
pubmed: 29723083
AIDS Patient Care STDS. 2021 Jul;35(7):249-254
pubmed: 34242090
AIDS Behav. 2020 Sep;24(9):2469-2472
pubmed: 32347404
HIV Res Clin Pract. 2021 Jun;22(3):63-70
pubmed: 34308800
AIDS Res Ther. 2020 Oct 4;17(1):59
pubmed: 33012282
J Gen Intern Med. 2002 May;17(5):377-81
pubmed: 12047736
AIDS Behav. 2007 Nov;11(6 Suppl):85-100
pubmed: 17682940
AIDS Care. 2020 Jan;32(1):98-103
pubmed: 31462060
Curr HIV/AIDS Rep. 2021 Apr;18(2):98-104
pubmed: 33616811
Clin Infect Dis. 2009 Jan 15;48(2):248-56
pubmed: 19072715
Clin Infect Dis. 2011 Mar 15;52(6):793-800
pubmed: 21367734
AIDS. 2020 Dec 1;34(15):2328-2331
pubmed: 32910069
Am J Public Health. 2021 May;111(5):835-838
pubmed: 33734837
AIDS Behav. 2020 Oct;24(10):2770-2772
pubmed: 32382823
AIDS. 2022 Mar 1;36(3):355-362
pubmed: 34711737
J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):574-80
pubmed: 23011397
Am J Public Health. 2015 Oct;105(10):2068-75
pubmed: 26270301